VAERS Explorer
Back to explore

Report #2884324

Received Feb 4, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Female
Age
Age unknown
State
—
Recovered
Not recovered
Vaccinated
Sep 18, 2025
Onset
Sep 19, 2025
Days to onset
1
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
VARZOSZOSTER (NO BRAND NAME)UNKNOWN MANUFACTURERUNKUNK—

Symptoms (9)

DysarthriaDysphagiaFacial paralysisMagnetic resonance imaging head normalMagnetic resonance imaging neck normalMuscular weaknessSpasmodic dysphoniaSpeech disorderTrigeminal neuralgia

Symptom narrative

trouble talking; spasmotic dysphonia; Right arm motor weakness; right facial droop; Trigeminal neuralgia on right; slurred speech; trouble swallowing liquids; This serious case was reported by a consumer and described the occurrence of facial droop in a 63-year-old female patient who received Herpes zoster (Shingles vaccine) for prophylaxis. Concurrent medical conditions included blood pressure abnormal, blood cholesterol abnormal, attention deficit hyperactivity disorder and asthma. Concomitant products included lisinopril and evolocumab (Repatha). On 18-SEP-2025, the patient received Shingles vaccine. On 19-SEP-2025, 1 days after receiving Shingles vaccine, the patient experienced facial droop (Verbatim: right facial droop) (serious criteria GSK medically significant), trigeminal neuralgia (Verbatim: Trigeminal neuralgia on right), slurred speech (Verbatim: slurred speech), swallowing difficult (Verbatim: trouble swallowing liquids), spasmodic dysphonia (Verbatim: spasmotic dysphonia) and weakness of arms (Verbatim: Right arm motor weakness). On an unknown date, the patient experienced speech disorder (Verbatim: trouble talking). The outcome of the facial droop, trigeminal neuralgia, slurred speech, swallowing difficult, spasmodic dysphonia and weakness of arms were not resolved and the outcome of the speech disorder was not reported. It was unknown if the reporter considered the facial droop, trigeminal neuralgia, slurred speech, swallowing difficult, speech disorder, spasmodic dysphonia and weakness of arms to be related to Shingles vaccine. The company considered the facial droop to be unrelated to Shingles vaccine. It was unknown if the company considered the trigeminal neuralgia, slurred speech, swallowing difficult, speech disorder, spasmodic dysphonia and weakness of arms to be related to Shingles vaccine. Additional Information: GSK Receipt Date: 28-JAN-2026 The symptoms were treated. The batch number was not provided and request for this information has been made.; Sender's Comments: A case of Facial paralysis 1 day after receiving Shingles vaccine, in a 63-year-old female patient. Based on the available information,?a?possible causality that the event was caused by the GSK product cannot be ascertained. Consent for further follow-up has not been received.

Current illness

Asthma; Attention deficit hyperactivity disorder; Blood cholesterol abnormal; Blood pressure abnormal

Other medications

LISINOPRIL; REPATHA

Lab data

Test Name: MRI; Result Unstructured Data: (Test Result:negative,Unit:unknown,Normal Low:,Normal High:) MRI or brain and neck were negative